StockNews.com Initiates Coverage on Evogene (NASDAQ:EVGN)

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a report published on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital cut their price target on shares of Evogene from $30.00 to $12.00 and set a buy rating for the company in a research note on Friday, August 23rd.

Evogene Trading Up 3.0 %

Shares of NASDAQ:EVGN opened at $2.58 on Wednesday. The business’s 50 day moving average is $3.27 and its 200-day moving average is $5.47. The firm has a market capitalization of $106.13 million, a PE ratio of -5.60 and a beta of 1.40. Evogene has a 1-year low of $2.29 and a 1-year high of $10.40.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.94). Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%. The business had revenue of $0.91 million during the quarter.

Institutional Investors Weigh In On Evogene

An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets increased its holdings in shares of Evogene Ltd. (NASDAQ:EVGN) by 30.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the period. BNP Paribas Financial Markets owned about 0.22% of Evogene worth $69,000 at the end of the most recent quarter. Institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.